Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2009

01-08-2009 | Original Article

Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease

Authors: Yukie Matsuyama, Hiroyuki Terawaki, Tomoyoshi Terada, Seiichi Era

Published in: Clinical and Experimental Nephrology | Issue 4/2009

Login to get access

Abstract

Background

Oxidative stress is enhanced in advanced chronic kidney disease (CKD) patients and recognized as a main contributor to cardiovascular disease. Carbonyl stress is also known to be enhanced in advanced CKD; however the precise relationship between oxidative stress and carbonyl stress is not clear. The aim of this study was to investigate potential relationships between oxidative stress, carbonyl stress, and renal function among predialysis patients with CKD.

Methods

A total of 32 predialysis CKD patients (22 male, 10 female) were divided into four groups according to their values for creatinine clearance (Ccr) (group A, ≥60 ml/min; group B, 45–59 ml/min; group C, 30–44 ml/min; group D, ≤29 ml/min). As main markers of oxidative and carbonyl stresses, the redox state of Cys-34 (free thiol group) of human serum albumin [HSA(Cys-34)-redox] and the carbonyl content of serum proteins were employed, respectively.

Results

The values for the fraction of both reversibly oxidized HSA [f(HNA-1)] and irreversibly oxidized HSA [f(HNA-2)] significantly increased with a decrease in renal function (group A, 21.0 ± 3.4 and 1.8 ± 0.3%; group D, 31.1 ± 4.1 and 2.7 ± 0.9%, respectively). The value for carbonyl content also significantly increased with a decrease in renal function (group A, 0.7 ± 0.1 nmol/mg protein; group D, 1.1 ± 0.2 nmol/mg protein). There was a significant positive correlation between carbonyl content and the f(HNA-2) value, while such a correlation was not observed between carbonyl content and the f(HNA-1) value, suggesting that there is a close relationship between serum protein carbonylation and irreversible albumin thiol oxidation.

Conclusions

There is a close relationship between oxidative stress and carbonyl stress and these are enhanced in correlation with the level of renal dysfunction among predialysis CKD patients.
Literature
1.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
2.
go back to reference Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama study. Kidney Int. 2005;68:228–36.CrossRefPubMed Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama study. Kidney Int. 2005;68:228–36.CrossRefPubMed
3.
go back to reference Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5.CrossRefPubMed Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5.CrossRefPubMed
4.
go back to reference Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524–32.PubMed Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524–32.PubMed
5.
go back to reference Terawaki H, Yoshimura K, Hasegawa T, et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004;66:1988–93.CrossRefPubMed Terawaki H, Yoshimura K, Hasegawa T, et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004;66:1988–93.CrossRefPubMed
6.
go back to reference Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47:42–50.CrossRefPubMed Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47:42–50.CrossRefPubMed
7.
go back to reference Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48:752–60.CrossRefPubMed Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48:752–60.CrossRefPubMed
8.
go back to reference Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet. 2000;356:1213–8.CrossRefPubMed Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet. 2000;356:1213–8.CrossRefPubMed
9.
go back to reference Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992–5.CrossRefPubMed Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992–5.CrossRefPubMed
10.
go back to reference Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919–25.CrossRefPubMed Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919–25.CrossRefPubMed
11.
go back to reference Nanayakkara PWB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease. Arch Intern Med. 2007;167:1262–70.CrossRefPubMed Nanayakkara PWB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease. Arch Intern Med. 2007;167:1262–70.CrossRefPubMed
12.
go back to reference Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–16.CrossRefPubMed Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–16.CrossRefPubMed
13.
go back to reference Agarwal R. Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol. 2004;61:377–83.CrossRefPubMed Agarwal R. Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol. 2004;61:377–83.CrossRefPubMed
14.
go back to reference Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int. 1999;55:389–99.CrossRefPubMed Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int. 1999;55:389–99.CrossRefPubMed
15.
go back to reference Peters T Jr. All about Albumin. Biochemistry, genetics, and medical applications. New York: Academic Press Inc; 1996. p. 9–75. Peters T Jr. All about Albumin. Biochemistry, genetics, and medical applications. New York: Academic Press Inc; 1996. p. 9–75.
16.
go back to reference Sogami M, Nagoka S, Era S, Honda M, Noguchi K. Resolution of mercapt- and non-mercaptalbumin by high-performance liquid chromatography. Int J Peptide Protein Res. 1984;24:96–103.CrossRef Sogami M, Nagoka S, Era S, Honda M, Noguchi K. Resolution of mercapt- and non-mercaptalbumin by high-performance liquid chromatography. Int J Peptide Protein Res. 1984;24:96–103.CrossRef
17.
go back to reference Sogami M, Era S, Nagaoka S, et al. HPLC-studies on nonmercapt-mercapt conversion of human serum albumin. Int J Peptide Protein Res. 1985;25:398–402.CrossRef Sogami M, Era S, Nagaoka S, et al. HPLC-studies on nonmercapt-mercapt conversion of human serum albumin. Int J Peptide Protein Res. 1985;25:398–402.CrossRef
18.
go back to reference Era S, Hamaguchi T, Sogami M, et al. Further studies on the resolution of human mercapt- and non-mercaptalbumin and on human serum albumin in the elderly by high-performance liquid chromatography. Int J Peptide Protein Res. 1988;31:435–42.CrossRef Era S, Hamaguchi T, Sogami M, et al. Further studies on the resolution of human mercapt- and non-mercaptalbumin and on human serum albumin in the elderly by high-performance liquid chromatography. Int J Peptide Protein Res. 1988;31:435–42.CrossRef
19.
go back to reference Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta. 1995;1247:12–6.CrossRefPubMed Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta. 1995;1247:12–6.CrossRefPubMed
20.
go back to reference Imai H, Hayashi T, Negawa T, et al. Strenuous exercise-induced change in redox state of human serum albumin during intensive kendo training. Jpn J Physiol. 2002;52:135–40.CrossRefPubMed Imai H, Hayashi T, Negawa T, et al. Strenuous exercise-induced change in redox state of human serum albumin during intensive kendo training. Jpn J Physiol. 2002;52:135–40.CrossRefPubMed
21.
go back to reference Sogami M, Era S, Nagaoka S, et al. High-performance liquid chromatographic studies on non-mercapt ↔ mercapt conversion of human serum albumin. II. J Chromatogr. 1985;332:19–27.CrossRefPubMed Sogami M, Era S, Nagaoka S, et al. High-performance liquid chromatographic studies on non-mercapt ↔ mercapt conversion of human serum albumin. II. J Chromatogr. 1985;332:19–27.CrossRefPubMed
22.
go back to reference Fukushima H, Miwa Y, Shiraki M, et al. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatol Res. 2007;37:765–70.CrossRefPubMed Fukushima H, Miwa Y, Shiraki M, et al. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatol Res. 2007;37:765–70.CrossRefPubMed
23.
go back to reference Soejima A, Kaneda F, Manno S, et al. Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kideny Dis. 2002;39:1040–6.CrossRefPubMed Soejima A, Kaneda F, Manno S, et al. Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kideny Dis. 2002;39:1040–6.CrossRefPubMed
24.
go back to reference Soejima A, Matsuzawa N, Hayashi T, et al. Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif. 2004;22:525–9.CrossRefPubMed Soejima A, Matsuzawa N, Hayashi T, et al. Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif. 2004;22:525–9.CrossRefPubMed
25.
go back to reference Terawaki H, Matsuyama Y, Era S, et al. Elevated oxidative stress measured as albumin redox state in continuous ambulatory peritoneal dialysis patients correlates with small uraemic solutes. Nephrol Dial Transplant. 2007;22:968.CrossRefPubMed Terawaki H, Matsuyama Y, Era S, et al. Elevated oxidative stress measured as albumin redox state in continuous ambulatory peritoneal dialysis patients correlates with small uraemic solutes. Nephrol Dial Transplant. 2007;22:968.CrossRefPubMed
26.
go back to reference Terawaki H, Nakayama K, Matsuyama Y, et al. Dialyzable uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients. Blood Purif. 2007;25:274–9.CrossRefPubMed Terawaki H, Nakayama K, Matsuyama Y, et al. Dialyzable uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients. Blood Purif. 2007;25:274–9.CrossRefPubMed
27.
go back to reference Suzuki E, Yasuda K, Takeda N, et al. Increased oxidized form of serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract. 1992;18:153–8.CrossRefPubMed Suzuki E, Yasuda K, Takeda N, et al. Increased oxidized form of serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract. 1992;18:153–8.CrossRefPubMed
28.
go back to reference Hayakawa A, Kuwata K, Era S, et al. Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B. 1997;698:27–33.CrossRef Hayakawa A, Kuwata K, Era S, et al. Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B. 1997;698:27–33.CrossRef
29.
go back to reference Hayashi T, Era S, Kawai K, et al. Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology. 2000;6:237–43.CrossRef Hayashi T, Era S, Kawai K, et al. Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology. 2000;6:237–43.CrossRef
30.
go back to reference Tomida M, Ishimaru J, Murayama K, et al. Intra-articular oxidative state correlated with the pathogenesis of disorders of the temporomandibular joint. Br J Oral Maxillofac Surg. 2004;42:405–9.CrossRefPubMed Tomida M, Ishimaru J, Murayama K, et al. Intra-articular oxidative state correlated with the pathogenesis of disorders of the temporomandibular joint. Br J Oral Maxillofac Surg. 2004;42:405–9.CrossRefPubMed
31.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed
32.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–266. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–266.
33.
go back to reference Chauhan DP, Gupta PH, Nampoothiri MRN, Singhal PC, Chugh KS, Nair CR. Determination of erythrocyte superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase, reduced glutathione and malonyldialdehyde in uremia. Clin Chim Acta. 1982;123:153–9.CrossRefPubMed Chauhan DP, Gupta PH, Nampoothiri MRN, Singhal PC, Chugh KS, Nair CR. Determination of erythrocyte superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase, reduced glutathione and malonyldialdehyde in uremia. Clin Chim Acta. 1982;123:153–9.CrossRefPubMed
34.
go back to reference Richard MJ, Arnaud J, Jurkovitz C, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron. 1991;57:10–5.CrossRefPubMed Richard MJ, Arnaud J, Jurkovitz C, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron. 1991;57:10–5.CrossRefPubMed
35.
go back to reference Shurtz-Swirski R, Mashiach E, Kristal B, Shkolnik T, Shasha SM. Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure. Nephron. 1995;71:176–9.CrossRefPubMed Shurtz-Swirski R, Mashiach E, Kristal B, Shkolnik T, Shasha SM. Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure. Nephron. 1995;71:176–9.CrossRefPubMed
36.
go back to reference Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999;51:233–41.PubMed Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999;51:233–41.PubMed
37.
go back to reference Martin-Mateo MC, Sánchez-Portugal M, Iglesias S, de Paula A, Bustamante J. Oxidative stress in chronic renal failure. Ren Fail. 1999;21:155–67.CrossRefPubMed Martin-Mateo MC, Sánchez-Portugal M, Iglesias S, de Paula A, Bustamante J. Oxidative stress in chronic renal failure. Ren Fail. 1999;21:155–67.CrossRefPubMed
38.
go back to reference Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail. 2001;23:563–71.CrossRefPubMed Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail. 2001;23:563–71.CrossRefPubMed
39.
go back to reference Hou FF, Ren H, Owen WF Jr, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol. 2004;15:1889–96.CrossRefPubMed Hou FF, Ren H, Owen WF Jr, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol. 2004;15:1889–96.CrossRefPubMed
40.
go back to reference Stauber RE, Oettl K, Stadlbauer V, Greilberger J, Krisper P, Lackner C. Redox state of albumin and carbonyl content of proteins are altered in acute-on-chronic liver failure. Hepatology. 2006;44(suppl 1):364. Stauber RE, Oettl K, Stadlbauer V, Greilberger J, Krisper P, Lackner C. Redox state of albumin and carbonyl content of proteins are altered in acute-on-chronic liver failure. Hepatology. 2006;44(suppl 1):364.
41.
go back to reference Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRefPubMed Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRefPubMed
42.
go back to reference Rule AD, Jacobsen SJ, Schwartz GL, et al. A comparison of serum creatinine-based methods for identifying chronic kidney disease in hypertensive individuals and their siblings. Am J Hypertens. 2006;19:608–14.CrossRefPubMed Rule AD, Jacobsen SJ, Schwartz GL, et al. A comparison of serum creatinine-based methods for identifying chronic kidney disease in hypertensive individuals and their siblings. Am J Hypertens. 2006;19:608–14.CrossRefPubMed
Metadata
Title
Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease
Authors
Yukie Matsuyama
Hiroyuki Terawaki
Tomoyoshi Terada
Seiichi Era
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0161-y

Other articles of this Issue 4/2009

Clinical and Experimental Nephrology 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.